bioAffinity Technologies News Update

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Lung Innovations Network Adds CyPath Lung Test to its Comprehensive Lung Care Practice

Lung Innovations Network is incorporating CyPath Lung, our noninvasive test for the early detection of lung cancer, into its patient-centered practice that offers comprehensive lung care to more than 10,000 patients in central and western Pennsylvania. Lung Innovations Network’s multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice. “I see hundreds of patients a year in my clinical practice who can directly benefit from CyPath Lung, bioAffinity’s patient-friendly, noninvasive test for lung cancer,” Medical Director Sandeep Bansal, M.D., said.

bioAffinity Expands Sales Team for CyPath Lung

National Sales Director Dallas Coleman announced that Cole Koeppen has joined bioAffinity Technologies as Pulmonary Sales Executive for CyPath Lung in North Texas. Cole most recently was Territory Sales Associate for Pulmonx Corporation, a provider of minimally invasive treatments for patients with chronic obstructive pulmonary disease (COPD). Prior to Pulmonx, Koeppen was Associate Territory Manager for Becton Dickinson & Company (BD), a global medical technology company. “Cole’s track record with both Pulmonx and BD demonstrates his talent for developing effective sales strategies, building long-term relationships with customers and meeting aggressive targets,” said Dallas. “I look forward to working with Cole to continue to expand our market share in North Texas.”

Sandeep Bansal, M.D., Joins bioAffinity Medical and Scientific Advisory Board

bioAffinity Technologies welcomes Dr. Bansal, Medical Director of Lung Innovations Network, to our Medical and Scientific Advisory Board. Board certified in pulmonary disease, critical care medicine and interventional pulmonology, Dr. Bansal has also served as principal investigator of multiple clinical research trials and peer reviewer for several medical journals. “Dr. Bansal’s experience as both clinician and researcher demonstrates his commitment to innovative healthcare and the best possible outcome for his patients,” bioAffinity Technologies President and CEO Maria Zannes said. “He will be a valuable voice on our advisory board.”